The Association Between Janus Kinase 2 and Factor V Leiden Mutations and Thrombotic Complications in Patients With Myeloproliferative Disorders: A Study From Saudi Arabia
Authors:
Open Access
- 25 November 2024
- journal article
- Published by Springer Nature in Cureus
- Vol. 16 (11)
Abstract
No abstract availableKeywords
This publication has 26 references indexed in Scilit:
- Genome-wide association analysis of venous thromboembolism identifies new risk loci and genetic overlap with arterial vascular diseaseNature Genetics, 2019
- JAK2V617F mutation is common in old patients with polycythemia vera and essential thrombocythemiaAging Clinical and Experimental Research, 2011
- Is JAK2 V617F mutation more than a diagnostic index?Leukemia Research, 2009
- The Myeloproliferative DisordersNew England Journal of Medicine, 2006
- The clinical phenotype of wild‐type, heterozygous, and homozygous JAK2V617F in polycythemia veraCancer, 2005
- JAK2V617F mutation in essential thrombocythaemia: clinical associations and long‐term prognostic relevanceBritish Journal of Haematology, 2005
- Clinical implications of the JAK2 V617F mutation in essential thrombocythemiaLeukemia, 2005
- Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosisCancer Cell, 2005
- Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disordersThe Lancet, 2005
- Factor V Leiden mutation carriership and venous thromboembolism in polycythemia vera and essential thrombocythemiaAmerican Journal of Hematology, 2002